The current financial score of Benitec Biopharma Inc is 6.60. Its financial status is robust, and its operating efficiency is low.
The current valuation score of Benitec Biopharma Inc is 8.50. Its current P/E ratio is -10.45, which is -294.76% below the recent high of 20.35 and -82.62% above the recent low of -19.08.
The current earnings forecast score of Benitec Biopharma Inc is 8.86. The average price target is 24.33, with a high of 32.00 and a low of 17.00.
The current price momentum score of Benitec Biopharma Inc is 4.98. Currently, the stock price is trading between the resistance level at 12.19 and the support level at 8.17, making it suitable for range-bound swing trading.
The current institutional shareholding score of Benitec Biopharma Inc is 10.00. The latest institutional shareholding proportion is 96.50%, representing a quarter-over-quarter increase of 36.64%.
The current risk assessment score of Benitec Biopharma Inc is 3.67. The company's beta value is 0.28. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.